San Diego-dependent Viking Therapeutics marked itself as a serious competitor in the weight loss drug market place in February after revealing promising information from a mid-stage demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection As well as in March the co